|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT02421978 |
|
Date of registration:
|
16/04/2015 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Inflammation-Induced CNS Glutamate During Breast Cancer Treatment
|
|
Scientific title:
|
Inflammation-Induced CNS Glutamate During Breast Cancer Treatment |
|
Date of first enrolment:
|
May 2015 |
|
Target sample size:
|
98 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT02421978 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Andrew H Miller, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Emory University |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Female breast cancer patients will have undergone surgery (lumpectomy or mastectomy)
with or without neoadjuvant or adjuvant chemotherapy
- Age between 21-65 years
Exclusion Criteria:
- Taking trastuzumab
Age minimum:
21 Years
Age maximum:
65 Years
Gender:
Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Breast Cancer
|
|
Primary Outcome(s)
|
|
Ratio of Glutamate to Creatine
[Time Frame: Baseline]
|
|
Behavioral assessments
[Time Frame: Baseline]
|
|
Cognitive dysfunction
[Time Frame: Baseline]
|
|
Levels of peripheral blood markers of inflammation
[Time Frame: Baseline]
|
|
Secondary ID(s)
|
|
IRB00080062
|
|
1R21MH105897
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|